These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

421 related items for PubMed ID: 21095450

  • 1. Clinical insights for cancer outcomes in renal transplant patients.
    Alberú J.
    Transplant Proc; 2010 Nov; 42(9 Suppl):S36-40. PubMed ID: 21095450
    [Abstract] [Full Text] [Related]

  • 2. Minimizing the risk of posttransplant malignancy.
    Campistol JM.
    Transplant Proc; 2008 Dec; 40(10 Suppl):S40-3. PubMed ID: 19100906
    [Abstract] [Full Text] [Related]

  • 3. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF, Sirolimus CONVERT Trial Study Group.
    Transplantation; 2009 Jan 27; 87(2):233-42. PubMed ID: 19155978
    [Abstract] [Full Text] [Related]

  • 4. [Minimizing the risk of cancer in transplant patients].
    Campistol JM.
    G Ital Nefrol; 2010 Jan 27; 27 Suppl 50():S81-5. PubMed ID: 20922701
    [Abstract] [Full Text] [Related]

  • 5. mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field?
    Rostaing L, Kamar N.
    J Nephrol; 2010 Jan 27; 23(2):133-42. PubMed ID: 20155724
    [Abstract] [Full Text] [Related]

  • 6. Can immunosuppressive strategies be used to reduce cancer risk in renal transplant patients?
    Geissler EK.
    Transplant Proc; 2010 Nov 27; 42(9 Suppl):S32-5. PubMed ID: 21095449
    [Abstract] [Full Text] [Related]

  • 7. Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial.
    Alberú J, Pascoe MD, Campistol JM, Schena FP, Rial Mdel C, Polinsky M, Neylan JF, Korth-Bradley J, Goldberg-Alberts R, Maller ES, Sirolimus CONVERT Trial Study Group.
    Transplantation; 2011 Aug 15; 92(3):303-10. PubMed ID: 21792049
    [Abstract] [Full Text] [Related]

  • 8. Conversion to sirolimus in posttransplant renal neoplasms.
    Lopez V, Gutierrez C, Cabello M, Burgos D, Sola E, Gonzalez-Molina M.
    Transplant Proc; 2007 Sep 15; 39(7):2264-6. PubMed ID: 17889158
    [Abstract] [Full Text] [Related]

  • 9. Steroid and calcineurin inhibitor-sparing protocols in kidney transplantation.
    Helal I, Chan L.
    Transplant Proc; 2011 Mar 15; 43(2):472-7. PubMed ID: 21440737
    [Abstract] [Full Text] [Related]

  • 10. Calcineurin inhibitor sparing regimens using m-target of rapamycin inhibitors: an opportunity to improve cardiovascular risk following kidney transplantation?
    Zeier M, Van Der Giet M.
    Transpl Int; 2011 Jan 15; 24(1):30-42. PubMed ID: 20642495
    [Abstract] [Full Text] [Related]

  • 11. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies.
    Mathew T, Kreis H, Friend P.
    Clin Transplant; 2004 Aug 15; 18(4):446-9. PubMed ID: 15233824
    [Abstract] [Full Text] [Related]

  • 12. Protocol conversion from a calcineurin inhibitor based therapy to sirolimus.
    Oberbauer R.
    Transplantation; 2009 Apr 27; 87(8 Suppl):S7-10. PubMed ID: 19384186
    [Abstract] [Full Text] [Related]

  • 13. Long-term maintenance therapy with calcineurin inhibitors: an update.
    Campistol JM.
    Transplant Proc; 2010 Nov 27; 42(9 Suppl):S21-4. PubMed ID: 21095445
    [Abstract] [Full Text] [Related]

  • 14. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
    Uslu A, Töz H, Sen S, Alkan FT, Nart A, Aykas A, Doğan M, Postaci H, Sahin T, Simşek C.
    Transplant Proc; 2009 Mar 27; 41(2):756-63. PubMed ID: 19328973
    [Abstract] [Full Text] [Related]

  • 15. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V, Kamar N, Ribes D, Esposito L, Modesto A, Guitard J, Nasou G, Durand D, Rostaing L.
    Nephrol Dial Transplant; 2005 Nov 27; 20(11):2517-23. PubMed ID: 15985508
    [Abstract] [Full Text] [Related]

  • 16. Conversion to sirolimus in renal transplant recipients: a single-center experience.
    Yelken B, Caliskan Y, Ozkan O, Gorgulu N, Yazici H, Turkmen A, Sever MS.
    Artif Organs; 2010 Aug 27; 34(8):E230-7. PubMed ID: 20618227
    [Abstract] [Full Text] [Related]

  • 17. Improved 24-hour blood pressure control with sirolimus versus calcineurin inhibitor based immunosuppression in renal transplant recipients.
    Steigerwalt SP, Brar N, Dhungel A, Butcher D, Steigerwalt S, El-Ghouroury M, Provenzano R.
    Transplant Proc; 2009 Dec 27; 41(10):4184-7. PubMed ID: 20005365
    [Abstract] [Full Text] [Related]

  • 18. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation.
    Campistol JM, Eris J, Oberbauer R, Friend P, Hutchison B, Morales JM, Claesson K, Stallone G, Russ G, Rostaing L, Kreis H, Burke JT, Brault Y, Scarola JA, Neylan JF.
    J Am Soc Nephrol; 2006 Feb 27; 17(2):581-9. PubMed ID: 16434506
    [Abstract] [Full Text] [Related]

  • 19. Clinical evidence on the use of anti-mTOR drugs in renal transplantation.
    Hernández D, Martínez D, Gutiérrez E, López V, Gutiérrez C, García P, Cobelo C, Cabello M, Burgos D, Sola E, González-Molina M.
    Nefrologia; 2011 Feb 27; 31(1):27-34. PubMed ID: 21270910
    [Abstract] [Full Text] [Related]

  • 20. mTOR inhibitor-associated proteinuria in kidney transplant recipients.
    Diekmann F, Andrés A, Oppenheimer F.
    Transplant Rev (Orlando); 2012 Jan 27; 26(1):27-9. PubMed ID: 22137729
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.